SG11201509260RA - Chimeric fvii-xten molecules and uses thereof - Google Patents
Chimeric fvii-xten molecules and uses thereofInfo
- Publication number
- SG11201509260RA SG11201509260RA SG11201509260RA SG11201509260RA SG11201509260RA SG 11201509260R A SG11201509260R A SG 11201509260RA SG 11201509260R A SG11201509260R A SG 11201509260RA SG 11201509260R A SG11201509260R A SG 11201509260RA SG 11201509260R A SG11201509260R A SG 11201509260RA
- Authority
- SG
- Singapore
- Prior art keywords
- xten molecules
- chimeric fvii
- fvii
- chimeric
- xten
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829878P | 2013-05-31 | 2013-05-31 | |
US201361883707P | 2013-09-27 | 2013-09-27 | |
US201361901954P | 2013-11-08 | 2013-11-08 | |
US201461988105P | 2014-05-02 | 2014-05-02 | |
PCT/US2014/040370 WO2014194282A2 (en) | 2013-05-31 | 2014-05-30 | Chimeric fvii-xten molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201509260RA true SG11201509260RA (en) | 2015-12-30 |
Family
ID=51989548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509260RA SG11201509260RA (en) | 2013-05-31 | 2014-05-30 | Chimeric fvii-xten molecules and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20160115467A1 (en) |
EP (1) | EP3004159A2 (en) |
JP (1) | JP2016530218A (en) |
KR (1) | KR20160013868A (en) |
CN (1) | CN105358569A (en) |
AU (1) | AU2014273881A1 (en) |
BR (1) | BR112015029387A2 (en) |
CA (1) | CA2912654A1 (en) |
EA (1) | EA201592023A1 (en) |
PH (1) | PH12015502572A1 (en) |
SG (1) | SG11201509260RA (en) |
TW (1) | TW201536811A (en) |
WO (1) | WO2014194282A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
KR20190094480A (en) | 2012-02-15 | 2019-08-13 | 바이오버라티브 테라퓨틱스 인크. | Recombinant factor viii proteins |
CN111548418A (en) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | Factor VIII compositions and methods of making and using same |
US10364288B2 (en) | 2013-05-24 | 2019-07-30 | Biogen Ma Inc. | Anti-GPIIB/IIIA antibodies or uses thereof |
TW202003554A (en) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | Factor VIII-XTEN fusions and uses thereof |
MA40835A (en) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES |
CN114409783A (en) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | Anti-human transferrin receptor antibodies across the blood brain barrier |
CN107849150B (en) | 2015-06-24 | 2021-12-14 | Jcr制药股份有限公司 | Fusion proteins comprising BDNF |
JP6909203B2 (en) | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | Factor IX fusion proteins and their production and usage |
WO2017040344A2 (en) | 2015-08-28 | 2017-03-09 | Amunix Operating Inc. | Chimeric polypeptide assembly and methods of making and using the same |
MX2018010485A (en) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Antibodies to tigit. |
CN106226535B (en) * | 2016-08-01 | 2018-03-09 | 中国科学院广州生物医药与健康研究院 | Purposes of the CD61 as hemogenic endothelium cell sign thing |
CN107759696A (en) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | Fusion protein of human interleukin 7 and preparation method thereof |
CN106279437B (en) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
AR110586A1 (en) | 2016-12-26 | 2019-04-10 | Japan Chem Res | HUMAN ANTITRANSFERRINE RECEPTOR ANTIBODY THAT PENETRATES THE HEMATOENCEPHALIC BARRIER |
CN108727498B (en) * | 2018-04-24 | 2021-11-26 | 四川百利药业有限责任公司 | Cysteine engineered antibody-toxin conjugates |
CN109486907B (en) * | 2018-12-21 | 2022-02-11 | 陕西师范大学 | Loop-mediated isothermal amplification reagent capable of being transported at normal temperature, preparation method and application |
WO2021247591A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102348715B (en) * | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | Extension recombinant polypeptide and the composition for including the extension recombinant polypeptide |
WO2011069164A2 (en) * | 2009-12-06 | 2011-06-09 | Biogen Idec Ma Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
EP2591006B1 (en) * | 2010-07-09 | 2019-04-24 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
WO2012170969A2 (en) * | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
EA028914B1 (en) * | 2011-07-25 | 2018-01-31 | Байоджен Хемофилия Инк. | Assays to monitor bleeding disorders |
-
2014
- 2014-05-29 TW TW103118805A patent/TW201536811A/en unknown
- 2014-05-30 CN CN201480028641.6A patent/CN105358569A/en active Pending
- 2014-05-30 EA EA201592023A patent/EA201592023A1/en unknown
- 2014-05-30 JP JP2016517064A patent/JP2016530218A/en active Pending
- 2014-05-30 US US14/894,101 patent/US20160115467A1/en not_active Abandoned
- 2014-05-30 BR BR112015029387A patent/BR112015029387A2/en not_active IP Right Cessation
- 2014-05-30 WO PCT/US2014/040370 patent/WO2014194282A2/en active Application Filing
- 2014-05-30 CA CA2912654A patent/CA2912654A1/en not_active Abandoned
- 2014-05-30 SG SG11201509260RA patent/SG11201509260RA/en unknown
- 2014-05-30 AU AU2014273881A patent/AU2014273881A1/en not_active Abandoned
- 2014-05-30 KR KR1020157032744A patent/KR20160013868A/en not_active Application Discontinuation
- 2014-05-30 EP EP14804745.9A patent/EP3004159A2/en not_active Withdrawn
-
2015
- 2015-11-13 PH PH12015502572A patent/PH12015502572A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20160115467A1 (en) | 2016-04-28 |
WO2014194282A3 (en) | 2015-03-12 |
EP3004159A2 (en) | 2016-04-13 |
KR20160013868A (en) | 2016-02-05 |
BR112015029387A2 (en) | 2017-09-19 |
PH12015502572A1 (en) | 2016-02-29 |
EA201592023A1 (en) | 2016-07-29 |
JP2016530218A (en) | 2016-09-29 |
CA2912654A1 (en) | 2014-12-04 |
WO2014194282A2 (en) | 2014-12-04 |
CN105358569A (en) | 2016-02-24 |
TW201536811A (en) | 2015-10-01 |
AU2014273881A1 (en) | 2015-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274355B (en) | Aza-pyridone compounds and uses thereof | |
IL261743B (en) | Anti-il-33 antibodies and uses thereof | |
IL246287A0 (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
SG11201509260RA (en) | Chimeric fvii-xten molecules and uses thereof | |
HK1214275A1 (en) | Bispecific-fc molecules fc | |
HK1214969A1 (en) | Anti-pdgfr-beta antibodies and uses thereof -pdgfr- | |
IL261547B (en) | Anti-hepcidin antibodies and uses thereof | |
IL243974B (en) | Anti-prlr antibodies and uses thereof | |
IL245733A0 (en) | Aplnr modulators and uses thereof | |
EP3052511A4 (en) | Polynucleotide molecules and uses thereof | |
EP3052479A4 (en) | Polynucleotide molecules and uses thereof | |
GB201323008D0 (en) | Compounds and uses thereof | |
ZA201604048B (en) | Immunoglobulin-like molecules directed against fibronectin-eda | |
GB201307233D0 (en) | Compounds and uses thereof | |
GB201307989D0 (en) | Novel combinations and use | |
GB201320992D0 (en) | Complex and uses thereof | |
GB201302878D0 (en) | Modified igG molecules | |
HK1223307A1 (en) | Novel compounds and uses thereof | |
GB201309180D0 (en) | Compounds and Their Uses | |
GB201314610D0 (en) | Compounds and their uses | |
GB201306248D0 (en) | Compounds and their uses | |
ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
ZA201603596B (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
IL242818B (en) | Il-1beta-il-1ra chimera and methods of using the same | |
GB201323005D0 (en) | Compounds and uses thereof |